title: [Tick-borne encephalitis with fulminant course and lethal outcome in patients after plural vaccination].
abstract: In the Kurgan region, the Siberian subtype of the tick-borne encephalitis virus (TBEV) is dominant. The vaccines prepared from Far-Eastern TBEV subtype are used in this area. Among TBE patients in 2007-2011, 23.79% were vaccinated according to complete or incomplete course. 76.9% of persons were vaccinated with Encevir vaccine, Tomsk. An unusual focal form of TBE with fulminant disease with lethal outcome was developed in a patient who was vaccinated 6 times with heterotype vaccines produced using the strains of the Far-Eastern TBE subtype. Inoculation of immunoglobulin in hospital produced aggravation of clinical symptoms, development of convulsions, brain oedema, and respiratory distress syndrome. The disease continues only 55 hours from first symptoms to fatal outcome. Siberian subtype of TBEV was isolated from patient spinal cord (Kurgan-118-2010 strain). Possible mechanisms of this disease are discussed.
authors.forename: V V
authors.initials: VV
authors.lastname: Pogodina
authors.forename: L S
authors.initials: LS
authors.lastname: Levina
authors.forename: S M
authors.initials: SM
authors.lastname: Skrynnik
authors.forename: N S
authors.initials: NS
authors.lastname: Travina
authors.forename: L S
authors.initials: LS
authors.lastname: Karan'
authors.forename: N M
authors.initials: NM
authors.lastname: Kolesnikova
authors.forename: V Ia
authors.initials: VIa
authors.lastname: Karmysheva
authors.forename: S G
authors.initials: SG
authors.lastname: Gerasimov
authors.forename: G V
authors.initials: GV
authors.lastname: Malenko
authors.forename: L V
authors.initials: LV
authors.lastname: Perminov
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001929:Brain Edema / Q000139:chemically induced / Q000276:immunology / Q000821:virology; D004669:Encephalitis Viruses, Tick-Borne; D004675:Encephalitis, Tick-Borne / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000276:immunology / Q000821:virology; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D007136:Immunoglobulins; D014765:Viral Vaccines